Immunic, Inc. Announces Closing of $45.0 Million Public Offering
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of select…
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of select…
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of select…
Andre Achtstaetter acted as moderator of the session “Online Services in the Microfinance Market: Challenges and Growth…
Meetrics, Europas führender Anbieter für die umfassende Qualitätsprüfung digitaler Werbeplatzierungen, hat seine dritte…
4SC AG (4SC, FSE Prime Standard: VSC), today published the financial results of the 4SC Group for the financial year end…
Die 4SC AG (4SC, FWB Prime Standard: VSC) hat heute die Konzern-Finanzergebnisse für das am 31. Dezember 2015 abgelaufen…
Innovatives Produktupdate fĂĽr den Ad Attention Manager: „Reasons for Non-Viewability“ NamhaftÂe Neukunden in Frankreich…
Das BiotechnologieunternÂehmen 4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), das zielgerichtete, niedermol…
. - 4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucia…
Das BiotechnologieunternÂehmen 4SC AG (Frankfurt, Prime Standard: VSC), das zielgerichtete, niedermolekulare Medikamente…